BJMO - volume 12, issue 2, march 2018
Ir A. Hébrant PhD, E. Van Valckenborgh PhD, R. Salgado MD, PhD, G. Froyen PhD, F. Hulstaert MD, D. Roberfroid MD, PhD, S. Tejpar MD, PhD, A. Jouret-Mourin MD, PhD, M. Van den Bulcke PhD, A. Waeytens PhD
Molecular diagnostics in cancer aiming at improving diagnosis, prognosis and treatment are constantly exposed to new opportunities and challenges. The Belgian Commission of Personalised Medicine (ComPer-Med) has been created to advise the Federal Government on all matters related to personalised medicine in oncology, including the reimbursement of molecular tests. Here, we propose the Belgian strategy for molecular testing within a scientific based framework and its implementation in the Belgian healthcare system. For each tested biomarker a clinical test level is attached, which is key to establish the relevance of the test and to define the reimbursement.
(BELG J MED ONCOL 2018;12(2):46–50)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
